ChloroquineV1, Istex, Corpus, bibRecord, 001B71

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

Identifieur interne : 001B71 ( Istex/Corpus ); précédent : 001B70; suivant : 001B72

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

Auteurs : A. Delluc ; N. Limal ; X. Puéchal ; C. Francès ; J C Piette ; P. Cacoub

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2008-02.

RBID : ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3

English descriptors

Teeft :
- Acad, Acad dermatol, Adalimumab, Adalimumab refutes, Alveolar lung condensations, Anakinra, Anakinra introduction, Antagonist, Antimalarial, Apoptosis, April, Arthritis rheum bourke, Azathioprine, Bernier, Biochem, Biochem pharmacol lagneaux, Bourke, Bron, Cacoub, Cacoub1, Carlier, Case report, Cell type, Centre hospitalier, Characterised, Chemoattractant, Chemokines, Clin, Clin rheumatol, Cnrs, Colchicine, Control anakinra, Corticosteroid, Costenbader, Cyclophosphamide, Cytokine, Delforge, Dense neutrophilic, Dermal, Dermatol, Dermatol dinarello, Dermatosis, Dinarello, Disease activity, Disease concepts, Disulone, Dose prednisone, Dramatic efficacy, Drug effects, Drug responses, Early induction, Egurbide, Engl, Epidermal, Epidermal staining, Erythematosus, Erythematous, Erythrocyte, Erythrocyte sedimentation rate, Experimental breast cancer agents, February, First time, France correspondence, Garmendia, Giasuddin, Good efficacy, Haematol, Haematol efficacy, Haemolysis, Histopathologic, Histopathologic evidence, Hopital, Hopital service, Hospitalier, Human breast cancer cell model, Human receptor antagonist, Hydroxychloroquine, Immortal time bias, Immunohistochemical, Immunohistochemical study, Immunosuppressive, Immunosuppressive drugs, Increase production, Inflammation, Inflammatory, Inflammatory disease, Interleukin, January, July, Kinereth, Kurzrock, Laboratory signs, Lagneaux, Lesion, Leukaemia, Lower staining, Lupus, Lymphocyte, Lymphocytic, Lymphocytic leukaemia cells, Macrophage, Major pathophysiological role, Many worlds, Marie curie paris, Martinezberriotxoa, Martirosyan, Massy, Mature neutrophils, Medecine, Mediator, Methotrexate, Natural inhibitor, Neutrophil, Neutrophilia, Neutrophilic, Neutrophilic dermatosis characterised, Nitric, Nitric oxide, Normal control subjects, Observational studies, Online, Pathological study, Pathophysiological, Pharmacoepidemiol, Pharmacoepidemiol drug, Pharmacol, Pijoan, Possible mediator, Previous studies, Prostaglandin, Pulmonary involvement, Quinolines, Radiological, Radiological remission, Randomised, Receptor, Receptor antagonist, Receptor antagonist anakinra kinereth, Recombinant, Recombinant form, Recurrent fever, Refractory, Refutes, Remission, Remodelling, Rheum, Rheumatol, Rhumatologie, Right flank, Same treatment regimen, Secrete, September, Serum levels, Severe haemolysis, Significant reduction, Skin lesions, Specific intervention, Specific neutrophil chemoattractant, Strobl, Study5, Subcutaneously, Suissa, Survival factors, Syndrome, Systemic lupus erythematosus, Tender erythematous skin lesions, Tissue remodelling, Tumour, Tumour necrosis factor, Type1, Type1 receptor, Ugarte, Universite pierre, Various functions, White blood cells.

Url:

https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.pdf

DOI: 10.1136/ard.2006.068254

Links to Exploration step

ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<author><name sortKey="Delluc, A" sort="Delluc, A" uniqKey="Delluc A" first="A" last="Delluc">A. Delluc</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Limal, N" sort="Limal, N" uniqKey="Limal N" first="N" last="Limal">N. Limal</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Puechal, X" sort="Puechal, X" uniqKey="Puechal X" first="X" last="Puéchal">X. Puéchal</name>
<affiliation><mods:affiliation>Service de Rhumatologie, Centre Hospitalier du Mans, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Frances, C" sort="Frances, C" uniqKey="Frances C" first="C" last="Francès">C. Francès</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Piette, J C" sort="Piette, J C" uniqKey="Piette J" first="J C" last="Piette">J C Piette</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cacoub, P" sort="Cacoub, P" uniqKey="Cacoub P" first="P" last="Cacoub">P. Cacoub</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1136/ard.2006.068254</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B71</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<author><name sortKey="Delluc, A" sort="Delluc, A" uniqKey="Delluc A" first="A" last="Delluc">A. Delluc</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Limal, N" sort="Limal, N" uniqKey="Limal N" first="N" last="Limal">N. Limal</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Puechal, X" sort="Puechal, X" uniqKey="Puechal X" first="X" last="Puéchal">X. Puéchal</name>
<affiliation><mods:affiliation>Service de Rhumatologie, Centre Hospitalier du Mans, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Frances, C" sort="Frances, C" uniqKey="Frances C" first="C" last="Francès">C. Francès</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Piette, J C" sort="Piette, J C" uniqKey="Piette J" first="J C" last="Piette">J C Piette</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cacoub, P" sort="Cacoub, P" uniqKey="Cacoub P" first="P" last="Cacoub">P. Cacoub</name>
<affiliation><mods:affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2008-02">2008-02</date>
<biblScope unit="volume">67</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="278">278</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Acad dermatol</term>
<term>Adalimumab</term>
<term>Adalimumab refutes</term>
<term>Alveolar lung condensations</term>
<term>Anakinra</term>
<term>Anakinra introduction</term>
<term>Antagonist</term>
<term>Antimalarial</term>
<term>Apoptosis</term>
<term>April</term>
<term>Arthritis rheum bourke</term>
<term>Azathioprine</term>
<term>Bernier</term>
<term>Biochem</term>
<term>Biochem pharmacol lagneaux</term>
<term>Bourke</term>
<term>Bron</term>
<term>Cacoub</term>
<term>Cacoub1</term>
<term>Carlier</term>
<term>Case report</term>
<term>Cell type</term>
<term>Centre hospitalier</term>
<term>Characterised</term>
<term>Chemoattractant</term>
<term>Chemokines</term>
<term>Clin</term>
<term>Clin rheumatol</term>
<term>Cnrs</term>
<term>Colchicine</term>
<term>Control anakinra</term>
<term>Corticosteroid</term>
<term>Costenbader</term>
<term>Cyclophosphamide</term>
<term>Cytokine</term>
<term>Delforge</term>
<term>Dense neutrophilic</term>
<term>Dermal</term>
<term>Dermatol</term>
<term>Dermatol dinarello</term>
<term>Dermatosis</term>
<term>Dinarello</term>
<term>Disease activity</term>
<term>Disease concepts</term>
<term>Disulone</term>
<term>Dose prednisone</term>
<term>Dramatic efficacy</term>
<term>Drug effects</term>
<term>Drug responses</term>
<term>Early induction</term>
<term>Egurbide</term>
<term>Engl</term>
<term>Epidermal</term>
<term>Epidermal staining</term>
<term>Erythematosus</term>
<term>Erythematous</term>
<term>Erythrocyte</term>
<term>Erythrocyte sedimentation rate</term>
<term>Experimental breast cancer agents</term>
<term>February</term>
<term>First time</term>
<term>France correspondence</term>
<term>Garmendia</term>
<term>Giasuddin</term>
<term>Good efficacy</term>
<term>Haematol</term>
<term>Haematol efficacy</term>
<term>Haemolysis</term>
<term>Histopathologic</term>
<term>Histopathologic evidence</term>
<term>Hopital</term>
<term>Hopital service</term>
<term>Hospitalier</term>
<term>Human breast cancer cell model</term>
<term>Human receptor antagonist</term>
<term>Hydroxychloroquine</term>
<term>Immortal time bias</term>
<term>Immunohistochemical</term>
<term>Immunohistochemical study</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive drugs</term>
<term>Increase production</term>
<term>Inflammation</term>
<term>Inflammatory</term>
<term>Inflammatory disease</term>
<term>Interleukin</term>
<term>January</term>
<term>July</term>
<term>Kinereth</term>
<term>Kurzrock</term>
<term>Laboratory signs</term>
<term>Lagneaux</term>
<term>Lesion</term>
<term>Leukaemia</term>
<term>Lower staining</term>
<term>Lupus</term>
<term>Lymphocyte</term>
<term>Lymphocytic</term>
<term>Lymphocytic leukaemia cells</term>
<term>Macrophage</term>
<term>Major pathophysiological role</term>
<term>Many worlds</term>
<term>Marie curie paris</term>
<term>Martinezberriotxoa</term>
<term>Martirosyan</term>
<term>Massy</term>
<term>Mature neutrophils</term>
<term>Medecine</term>
<term>Mediator</term>
<term>Methotrexate</term>
<term>Natural inhibitor</term>
<term>Neutrophil</term>
<term>Neutrophilia</term>
<term>Neutrophilic</term>
<term>Neutrophilic dermatosis characterised</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Normal control subjects</term>
<term>Observational studies</term>
<term>Online</term>
<term>Pathological study</term>
<term>Pathophysiological</term>
<term>Pharmacoepidemiol</term>
<term>Pharmacoepidemiol drug</term>
<term>Pharmacol</term>
<term>Pijoan</term>
<term>Possible mediator</term>
<term>Previous studies</term>
<term>Prostaglandin</term>
<term>Pulmonary involvement</term>
<term>Quinolines</term>
<term>Radiological</term>
<term>Radiological remission</term>
<term>Randomised</term>
<term>Receptor</term>
<term>Receptor antagonist</term>
<term>Receptor antagonist anakinra kinereth</term>
<term>Recombinant</term>
<term>Recombinant form</term>
<term>Recurrent fever</term>
<term>Refractory</term>
<term>Refutes</term>
<term>Remission</term>
<term>Remodelling</term>
<term>Rheum</term>
<term>Rheumatol</term>
<term>Rhumatologie</term>
<term>Right flank</term>
<term>Same treatment regimen</term>
<term>Secrete</term>
<term>September</term>
<term>Serum levels</term>
<term>Severe haemolysis</term>
<term>Significant reduction</term>
<term>Skin lesions</term>
<term>Specific intervention</term>
<term>Specific neutrophil chemoattractant</term>
<term>Strobl</term>
<term>Study5</term>
<term>Subcutaneously</term>
<term>Suissa</term>
<term>Survival factors</term>
<term>Syndrome</term>
<term>Systemic lupus erythematosus</term>
<term>Tender erythematous skin lesions</term>
<term>Tissue remodelling</term>
<term>Tumour</term>
<term>Tumour necrosis factor</term>
<term>Type1</term>
<term>Type1 receptor</term>
<term>Ugarte</term>
<term>Universite pierre</term>
<term>Various functions</term>
<term>White blood cells</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<istex><corpusName>bmj</corpusName>
<keywords><teeft><json:string>receptor</json:string>
<json:string>anakinra</json:string>
<json:string>adalimumab</json:string>
<json:string>neutrophil</json:string>
<json:string>september</json:string>
<json:string>dermatol</json:string>
<json:string>dermatol dinarello</json:string>
<json:string>interleukin</json:string>
<json:string>skin lesions</json:string>
<json:string>radiological</json:string>
<json:string>july</json:string>
<json:string>receptor antagonist</json:string>
<json:string>dinarello</json:string>
<json:string>macrophage</json:string>
<json:string>dermal</json:string>
<json:string>hopital</json:string>
<json:string>hopital service</json:string>
<json:string>neutrophilic</json:string>
<json:string>lupus</json:string>
<json:string>erythematosus</json:string>
<json:string>systemic lupus erythematosus</json:string>
<json:string>rheum</json:string>
<json:string>syndrome</json:string>
<json:string>tumour necrosis factor</json:string>
<json:string>quinolines</json:string>
<json:string>acad dermatol</json:string>
<json:string>experimental breast cancer agents</json:string>
<json:string>acad</json:string>
<json:string>human breast cancer cell model</json:string>
<json:string>biochem</json:string>
<json:string>dermatosis</json:string>
<json:string>characterised</json:string>
<json:string>neutrophilic dermatosis characterised</json:string>
<json:string>neutrophilia</json:string>
<json:string>erythematous</json:string>
<json:string>cytokine</json:string>
<json:string>tender erythematous skin lesions</json:string>
<json:string>pharmacol</json:string>
<json:string>mature neutrophils</json:string>
<json:string>drug responses</json:string>
<json:string>randomised</json:string>
<json:string>first time</json:string>
<json:string>dramatic efficacy</json:string>
<json:string>lagneaux</json:string>
<json:string>case report</json:string>
<json:string>recurrent fever</json:string>
<json:string>pulmonary involvement</json:string>
<json:string>alveolar lung condensations</json:string>
<json:string>erythrocyte</json:string>
<json:string>erythrocyte sedimentation rate</json:string>
<json:string>cell type</json:string>
<json:string>inflammatory disease</json:string>
<json:string>biochem pharmacol lagneaux</json:string>
<json:string>right flank</json:string>
<json:string>histopathologic</json:string>
<json:string>histopathologic evidence</json:string>
<json:string>dense neutrophilic</json:string>
<json:string>delforge</json:string>
<json:string>laboratory signs</json:string>
<json:string>january</json:string>
<json:string>colchicine</json:string>
<json:string>methotrexate</json:string>
<json:string>carlier</json:string>
<json:string>massy</json:string>
<json:string>disulone</json:string>
<json:string>haemolysis</json:string>
<json:string>severe haemolysis</json:string>
<json:string>immunosuppressive</json:string>
<json:string>immunosuppressive drugs</json:string>
<json:string>azathioprine</json:string>
<json:string>cyclophosphamide</json:string>
<json:string>bernier</json:string>
<json:string>good efficacy</json:string>
<json:string>kinereth</json:string>
<json:string>receptor antagonist anakinra kinereth</json:string>
<json:string>subcutaneously</json:string>
<json:string>significant reduction</json:string>
<json:string>white blood cells</json:string>
<json:string>anakinra introduction</json:string>
<json:string>april</json:string>
<json:string>same treatment regimen</json:string>
<json:string>dose prednisone</json:string>
<json:string>remission</json:string>
<json:string>radiological remission</json:string>
<json:string>refutes</json:string>
<json:string>adalimumab refutes</json:string>
<json:string>tumour</json:string>
<json:string>strobl</json:string>
<json:string>natural inhibitor</json:string>
<json:string>recombinant</json:string>
<json:string>recombinant form</json:string>
<json:string>human receptor antagonist</json:string>
<json:string>type1</json:string>
<json:string>type1 receptor</json:string>
<json:string>previous studies</json:string>
<json:string>mediator</json:string>
<json:string>possible mediator</json:string>
<json:string>prostaglandin</json:string>
<json:string>nitric</json:string>
<json:string>nitric oxide</json:string>
<json:string>various functions</json:string>
<json:string>giasuddin</json:string>
<json:string>remodelling</json:string>
<json:string>tissue remodelling</json:string>
<json:string>chemokines</json:string>
<json:string>bron</json:string>
<json:string>lymphocyte</json:string>
<json:string>secrete</json:string>
<json:string>increase production</json:string>
<json:string>chemoattractant</json:string>
<json:string>specific neutrophil chemoattractant</json:string>
<json:string>study5</json:string>
<json:string>serum levels</json:string>
<json:string>normal control subjects</json:string>
<json:string>pathological study</json:string>
<json:string>early induction</json:string>
<json:string>lower staining</json:string>
<json:string>control anakinra</json:string>
<json:string>corticosteroid</json:string>
<json:string>disease activity</json:string>
<json:string>cacoub1</json:string>
<json:string>universite pierre</json:string>
<json:string>marie curie paris</json:string>
<json:string>cnrs</json:string>
<json:string>apoptosis</json:string>
<json:string>lymphocytic</json:string>
<json:string>engl</json:string>
<json:string>rhumatologie</json:string>
<json:string>hospitalier</json:string>
<json:string>centre hospitalier</json:string>
<json:string>france correspondence</json:string>
<json:string>cacoub</json:string>
<json:string>leukaemia</json:string>
<json:string>specific intervention</json:string>
<json:string>pathophysiological</json:string>
<json:string>major pathophysiological role</json:string>
<json:string>ugarte</json:string>
<json:string>egurbide</json:string>
<json:string>garmendia</json:string>
<json:string>pijoan</json:string>
<json:string>martinezberriotxoa</json:string>
<json:string>antimalarial</json:string>
<json:string>lymphocytic leukaemia cells</json:string>
<json:string>hydroxychloroquine</json:string>
<json:string>survival factors</json:string>
<json:string>costenbader</json:string>
<json:string>clin</json:string>
<json:string>rheumatol</json:string>
<json:string>clin rheumatol</json:string>
<json:string>online</json:string>
<json:string>suissa</json:string>
<json:string>immortal time bias</json:string>
<json:string>observational studies</json:string>
<json:string>drug effects</json:string>
<json:string>pharmacoepidemiol</json:string>
<json:string>pharmacoepidemiol drug</json:string>
<json:string>kurzrock</json:string>
<json:string>disease concepts</json:string>
<json:string>haematol</json:string>
<json:string>haematol efficacy</json:string>
<json:string>martirosyan</json:string>
<json:string>many worlds</json:string>
<json:string>bourke</json:string>
<json:string>arthritis rheum bourke</json:string>
<json:string>immunohistochemical</json:string>
<json:string>immunohistochemical study</json:string>
<json:string>epidermal</json:string>
<json:string>epidermal staining</json:string>
<json:string>february</json:string>
<json:string>medecine</json:string>
<json:string>inflammation</json:string>
<json:string>inflammatory</json:string>
<json:string>refractory</json:string>
<json:string>antagonist</json:string>
<json:string>lesion</json:string>
</teeft>
</keywords>
<author><json:item><name>A Delluc</name>
<affiliations><json:string>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>N Limal</name>
<affiliations><json:string>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>X Puéchal</name>
<affiliations><json:string>Service de Rhumatologie, Centre Hospitalier du Mans, France</json:string>
</affiliations>
</json:item>
<json:item><name>C Francès</name>
<affiliations><json:string>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>J C Piette</name>
<affiliations><json:string>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>P Cacoub</name>
<affiliations><json:string>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</json:string>
</affiliations>
</json:item>
</author>
<articleId><json:string>ar68254</json:string>
</articleId>
<arkIstex>ark:/67375/NVC-H7PRWPXM-3</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<qualityIndicators><score>2.803</score>
<pdfWordCount>791</pdfWordCount>
<pdfCharCount>5338</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>1</pdfPageCount>
<pdfPageSize>595.276 x 793.701 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractWordCount>1</abstractWordCount>
<abstractCharCount>0</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<pmid><json:string>18192308</json:string>
</pmid>
<genre><json:string>research-article</json:string>
</genre>
<host><title>Annals of the Rheumatic Diseases</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0003-4967</json:string>
</issn>
<eissn><json:string>1468-2060</json:string>
</eissn>
<publisherId><json:string>ard</json:string>
</publisherId>
<volume>67</volume>
<issue>2</issue>
<pages><first>278</first>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>From September 2005 to April 2007</json:string>
<json:string>2008-01-11</json:string>
<json:string>1998</json:string>
<json:string>2002</json:string>
<json:string>2003</json:string>
</date>
<geogName></geogName>
<orgName><json:string>France Correspondence</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName></persName>
<placeName><json:string>Paris</json:string>
<json:string>France</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>September 2003</json:string>
<json:string>July 2002</json:string>
<json:string>September 2005</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/NVC-H7PRWPXM-3</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - rheumatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - arthritis & rheumatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Life Sciences</json:string>
<json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Immunology and Microbiology</json:string>
<json:string>3 - Immunology</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Immunology and Allergy</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Rheumatology</json:string>
</scopus>
</categories>
<publicationDate>2008</publicationDate>
<copyrightDate>2008</copyrightDate>
<doi><json:string>10.1136/ard.2006.068254</json:string>
</doi>
<id>E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<availability><licence><p>2008 BMJ Publishing Group and European League Against Rheumatism</p>
</licence>
<p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p>
</availability>
<date>2008-01-11</date>
</publicationStmt>
<notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
<author xml:id="author-0000"><persName><forename type="first">A</forename>
<surname>Delluc</surname>
</persName>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">N</forename>
<surname>Limal</surname>
</persName>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">X</forename>
<surname>Puéchal</surname>
</persName>
<affiliation>Service de Rhumatologie, Centre Hospitalier du Mans, France</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">C</forename>
<surname>Francès</surname>
</persName>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">J C</forename>
<surname>Piette</surname>
</persName>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">P</forename>
<surname>Cacoub</surname>
</persName>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
</author>
<idno type="istex">E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3</idno>
<idno type="ark">ark:/67375/NVC-H7PRWPXM-3</idno>
<idno type="DOI">10.1136/ard.2006.068254</idno>
<idno type="href">annrheumdis-67-278.pdf</idno>
<idno type="article-id">ar68254</idno>
<idno type="PMID">18192308</idno>
<idno type="local">annrheumdis;67/2/278</idno>
</analytic>
<monogr><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="pISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<idno type="publisher-id">ard</idno>
<idno type="PublisherID-hwp">annrheumdis</idno>
<idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2008-02"></date>
<biblScope unit="volume">67</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="278">278</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2008-01-11</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2008-01-11">Created</change>
<change when="2008-02">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id>
<journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id>
<journal-id journal-id-type="publisher-id">ard</journal-id>
<journal-title>Annals of the Rheumatic Diseases</journal-title>
<abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title>
<issn pub-type="ppub">0003-4967</issn>
<issn pub-type="epub">1468-2060</issn>
<publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="publisher-id">ar68254</article-id>
<article-id pub-id-type="doi">10.1136/ard.2006.068254</article-id>
<article-id pub-id-type="other">annrheumdis;67/2/278</article-id>
<article-id pub-id-type="pmid">18192308</article-id>
<article-id pub-id-type="other">278</article-id>
<article-id pub-id-type="other">ard.2006.068254</article-id>
<article-categories><subj-group subj-group-type="heading"><subject content-type="original">Letters</subject>
</subj-group>
</article-categories>
<title-group><article-title>Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</article-title>
<alt-title alt-title-type="running-head">Letters</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Delluc</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Limal</surname>
<given-names>N</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Puéchal</surname>
<given-names>X</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Francès</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Piette</surname>
<given-names>J C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cacoub</surname>
<given-names>P</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>
<addr-line>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</addr-line>
</aff>
<aff id="aff2"><label>2</label>
<addr-line>Service de Rhumatologie, Centre Hospitalier du Mans, France</addr-line>
</aff>
<author-notes><corresp>Professor P Cacoub, AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, F-75013 France; <email xlink:type="simple">patrice.cacoub@psl.aphp.fr</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>2</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="epub"><day>11</day>
<month>1</month>
<year>2008</year>
</pub-date>
<volume>67</volume>
<volume-id pub-id-type="other">67</volume-id>
<volume-id pub-id-type="other">67</volume-id>
<issue>2</issue>
<issue-id pub-id-type="other">annrheumdis;67/2</issue-id>
<issue-id pub-id-type="other">2</issue-id>
<issue-id pub-id-type="other">67/2</issue-id>
<fpage>278</fpage>
<history><date date-type="accepted"><day>1</day>
<month>7</month>
<year>2007</year>
</date>
</history>
<permissions><copyright-statement>2008 BMJ Publishing Group and European League Against Rheumatism</copyright-statement>
<copyright-year>2008</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-67-278.pdf"></self-uri>
</article-meta>
</front>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Delluc</namePart>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N</namePart>
<namePart type="family">Limal</namePart>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">X</namePart>
<namePart type="family">Puéchal</namePart>
<affiliation>Service de Rhumatologie, Centre Hospitalier du Mans, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Francès</namePart>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J C</namePart>
<namePart type="family">Piette</namePart>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P</namePart>
<namePart type="family">Cacoub</namePart>
<affiliation>Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<dateIssued encoding="w3cdtf">2008-02</dateIssued>
<dateCreated encoding="w3cdtf">2008-01-11</dateCreated>
<copyrightDate encoding="w3cdtf">2008</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Ann Rheum Dis</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0003-4967</identifier>
<identifier type="eISSN">1468-2060</identifier>
<identifier type="PublisherID">ard</identifier>
<identifier type="PublisherID-hwp">annrheumdis</identifier>
<identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>67</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>278</start>
</extent>
</part>
</relatedItem>
<identifier type="istex">E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3</identifier>
<identifier type="ark">ark:/67375/NVC-H7PRWPXM-3</identifier>
<identifier type="DOI">10.1136/ard.2006.068254</identifier>
<identifier type="href">annrheumdis-67-278.pdf</identifier>
<identifier type="ArticleID">ar68254</identifier>
<identifier type="PMID">18192308</identifier>
<identifier type="local">annrheumdis;67/2/278</identifier>
<accessCondition type="use and reproduction" contentType="copyright">2008 BMJ Publishing Group and European League Against Rheumatism</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource>
<recordOrigin>2008 BMJ Publishing Group and European League Against Rheumatism</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-H7PRWPXM-3/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B71 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001B71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:E7B93E2E4D5F0EDDEA3C9A407CA77705BC3BC8E3
   |texte=   Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri